Posts

Showing posts with the label 37-22

Dispensing Biotechnology Products: Handling, Professional Education, and Product Information

  Dispensing Biotechnology Products: Handling,  Professional Education, and Product Information   INTRODUCTION Preparation and/or dispensing of pharmaceuticals are primarily the responsibility of the pharmacist. Traditionally, parenteral products have been available in ready-to-use containers or required dilution with water or saline prior to use with no other special handling requirements. Hospital pharmacists, in particular, have prepared and dispensed parenteral products for individual patients for many years. While many pharmacists are skilled in handling parenteral products, biotechnology products may present additional challenges since they are proteins subject to denaturation and thus require special handling techniques. These challenges will be explained in greater detail in this chapter.

Pharmacist Reluctance

  PHARMACIST RELUCTANCE   Pharmacists may be reluctant to provide pharmaceutical care services to patients who require therapy with biotechnology drugs for a variety of reasons including (i) lack of knowledge about the tools of biotechnology; (ii) lack of understanding of the therapeutic aspects of recombinant protein products; (iii) lack of familiarity with the side effects and patient counseling information; (iv) lack of familiarity with the storage, handling and reconstitution of proteins; and (v) difficulty of handling reimbursement issues.   Pharmacists may view biotechnology drugs as quite different from traditional parenteral products like insulin and familiar oral dosage forms. However, in most respects, the services offered by pharmacists when dispensing biotechnology products are the same as those provided for traditional tablets or injectable products. It is important, regardless of the product being dispensed, to ensure that the patient understands the use, do...

Types of Information Needed by Pharmacists - Pharmacist Reluctance

Image
  Types of Information Needed by Pharmacists What types of information do pharmacists require to be confident providers of biotech drugs and services? For pharmacists who have been out of school for more than ten years, a contemporary understanding of the immune system, autoimmune diseases and mechanisms by which drugs modify the immune system is essential. Several appropriate books that can provide a basic background in immunology are listed in Table 1. Additionally, practitioners may enroll in organized courses or continuing education programs that can provide up-to-date information in the discipline of immunology. Current pharmacy students and recent graduates should be sufficiently trained in basic immunology as part of their professional curriculum.   Many pharmacists, upon hearing the word biotechnology, imagine a discipline too technical or  complicated to be understood by the typical practi-tioner. Pharmacists must recognize that biotechnology primarily refers to ...

Sources of Information for Pharmacists

Image
  Sources of Information for Pharmacists Many pharmacists do not know where to obtain the information that will allow them to be good providers of products of biotechnology. This textbook provides much of the essential background information in one source.   An excellent source of information on biotech-nology in general, and specific products in particular, is the biotech drug industry. Many manufacturer-sponsored programs are available describing ap-proved biotech products and those likely to come to market in the near future. Manufacturer programs provide extensive information about the disease states for which their products are indicated as well as product-specific information. Manufacturers are pre-pared to help pharmacists in the most effective provision of products and services to hospital-based and ambulatory patients. However, many pharma-cists are unaware of these services and how to obtain them. A web search of specific products will lead to the product and manufac...

The Pharmacist and Handling of Biotech Drugs

Image
  The Pharmacist and Handling of Biotech Drugs The pharmacist is responsible for the storage, preparation and dispensing of biotechnology drugs as well as patient education regarding the use of these products. In many cases, pharmacists must have additional training in order to be prepared for this role. This is especially true for pharmacists who practice in the ambulatory care setting since these products are increasingly available for administration by the patient in the home. Pharmacies of the future may stock pumps, patches, timed-release tablets, liposomes, implants, and vials of tailored monoclonal antibodies. With gene therapy and gene splicing on the horizon, it is possible that the pharmacist may eventually prepare and dispense gene therapy pro-ducts tailored for specific patients.   This chapter will discuss the general principles that pharmacists need to understand about storage, handling, preparation, administration of biotech pro-ducts and issues related to outpa...

Temperature Requirements - Pharmacist Reluctance

Image
  Temperature Requirements Since biotech products are primarily proteins, they are subject to denaturation when exposed to extreme temperatures. In general, most biotech products are shipped by the manufacturer in gel ice containers and need to be stored at 2 L C to 8 L C (Banga and Reddy, 1994). Once reconstituted, they should be stored under refrigeration until just prior to use. There are a few exceptions to this rule. For example, alteplase (tissue plasminogen activator) lyophilized powder is stable at room temperature for several years at temperatures not to exceed 30 L C (86 L F). However, after reconstitution, the product should be used within 8 hours (Genentech, 2005). For individual product temperature requirements, the product insert, product website or the manufacturer should be contacted. Table 3 lists temperature requirements for selected frequently prescribed products.     The variability between products with respect to temperature is exemplified by granulo...

Storage in Dosing and Administration Devices - Pharmacist Reluctance

  Storage in Dosing and Administration Devices Most biotech products may adhere to either plastic or glass containers such as syringes, polyvinyl chloride (PVC) intravenous bags, infusion equipment, and glass intravenous bottles. The effectiveness of the product may be reduced by three- or four-fold due to adherence. In order to decrease the amount of adherence, human serum albumin (HSA) is usually added to the solutions. The relative loss through adherence is concentration dependent,  i.e., the more concentrated the final solution the less significant the adherence becomes. The amount of HSA added varies with the product (Banga and Reddy, 1994; Koeller and Fields, 1991). Some products that require the addition of HSA include filgrastim, sargramostim, aldesleukin, erythropoietin and inter-feron- a . In the case of filgrastim, the addition of 2 mg/ mL of HSA to the final solution is required for concentrations of 5 to 15  m g/mL (Amgen, 2004). One mg of HSA per 1 mL 0.9% S...

Storage in IV Solutions and Light Protection - Pharmacist Reluctance

  Storage in IV Solutions Biotech product stability may vary when stored in different types of containers and syringes. Some products are only stable in plastic syringes, e.g., somatropin and erythropoietin, while others are stable in glass, polyvinyl chloride and polypropylene, e.g., aldesleukin. Batch prefilling of syringes is possible. However, it is important to make sure that programs. Determining how far in advance doses may be prepared is also an important consideration. G-CSF is stable in Becton Dickinson (B-D) disposable plastic syringes for up to 7 days (Amgen, 2004) while erythropoietin is stable for up to 14 days (Amgen, 2006). Aldesleukin is recommended to be adminis-tered in PVC although glass has been used in clinical trials with comparable results (Chiron, 2000). Solutions are stable for 48 hours when refrigerated. GM-CSF and G-CSF can be administered in either PVC or polypropylene (Berlex, 2004).   Light Protection Many biotech products are sensitive to light....

Mixing and Shaking - Pharmacist Reluctance

  Mixing and Shaking Improper handling of protein products can lead to denaturation. Shaking and severe agitation of most of these products will result in degradation. Therefore special techniques must be observed in preparing biotech products for use. Biotech products should not be shaken when adding any diluent as this may cause the product to break down. Once the diluent is added to the container, the vial should be swirled rather than vigorously shaken. Some shaking during transport may be unavoidable and proper inspection of products should occur to make sure the products have not been damaged during transit. When a product is affected by excessive shaking, physical separation or frothing within the vial of liquid products can usually be observed. For lyophilized products, agitation is not harmful until the product has been reconstituted. In distributing individual products to patient or ward areas, pneumatic tubes should be avoided.

Travel Requirements - Pharmacist Reluctance

  Travel Requirements When patients travel with these products, certain precautions should be observed. The drugs should be stored in insulated, cool containers. This can be accomplished by using ice packs to keep the biotech drug at the proper temperature in warmer climates, whereas the insulated container in colder climates may be all that is required. When traveling in sub-freezing weather, the products should be protected from freezing (temperatures below 2 L C). Keeping biotech drugs at proper temperature during auto-mobile travel may present a problem with tempera-tures inside a parked car often exceeding 37 L C (100 L F) on a warm day. Patients and delivery personnel must take care not to leave products that are not in insulated containers inside the car, trunk or glove compartment while shopping or making deliveries. When ice is used, care should be taken not to place the product directly on the ice. Dry ice should be avoided since it has the potential for freezing the prod...

Preparation of Biotechnology Products

  PREPARATION When preparing biotech products, aseptic technique must be employed as it is with traditional parenteral products. The product should be prepared in a clean room designed for this purpose with laminar air flow hoods, etc. Most of the products require reconstitu-tion with sterile water or bacteriostatic water for injection depending on stability data. The compat-ibility of individual products varies and limited data are available. As mentioned previously, when adding diluent to these products, care should be taken not to shake them, but to swirl the container or roll it between the palms of the hands. In the case of lyophilized products, introduction of the diluent should be directed down the side of the vial and not directly on the powder to avoid denaturing the protein. It is important to mention that stability does not mean sterility. Biotech products require the same precautions as any other parenteral product. Sterility is particularly important when pre-filling a...

Administration of Biotechnology Products

  ADMINISTRATION Prior to administering these products, pharmacists will need to use caution in reviewing dosage regimens. A potential source of medication error is the variation in units of measure for the various products. Some products are dosed in micrograms/kilogram ( m g/kg) rather than milligrams/kilogram (mg/kg). Also, some units of measure may be unique to the product, e.g., Chiron or Roche units. Dosage calculations need to be carefully checked to avoid potential errors.   Routes of Administration Biotech products are primarily administered parent-erally although many other routes of administration are in development. Some products may be given by either the intravenous or subcutaneous route while others are restricted to the subcutaneous or intramus-cular routes. In some cases, manufacturers have information on unapproved routes of administration or other new information that may be available by contacting the individual manufacturer. In any case, the manufacturer s...

Biogenerics - A Future Consideration?

  BIOGENERICS - A FUTURE CONSIDERATION?   A huge potential exists for the development of biogeneric products or generic versions of existing biotech drugs. Another term, follow-on protein, is sometimes used to describe the same concept. It is estimated that biogenerics could be available in the United States as early as 2009. Factors driving the development of biogenerics include the growing number of products, size of the biotech drug market, and the high cost of existing patent-protected products.   The Food and Drug Administration (FDA) has said that creating generic versions of these drugs will be difficult due to the complexity of these products. It will be difficult, if not impossible, to demonstrate an equivalent chemical structure for biogenerics. However, legislation may be introduced to develop a regulatory process (none currently exists in the United States) for approval of this type of product.   The biotech market already contains several types of insuli...

Outpatient/Home Care Issues of Biotechnology Products

Image
  OUTPATIENT/HOME CARE ISSUES As mentioned previously, the management of patients in the outpatient and home settings is now an accepted aspect of health care delivery. The use of biotech products outside the hospital is no exception to this trend. Home infusion and specialty pharmacy services dispense all forms of parenteral and enteral products including biotech drugs. These pharmacies have grown exponentially in the last twenty years due to cost savings for third party payers, technological advances that allow these services to occur in the home, and patient preference to be treated at home rather than an in-patient setting.   Patient Assessment and Education   Before a patient can be a candidate for home therapy, an assessment of the patient’s capabilities must occur. The patient, family member, or caregiver will need to be able to administer the medication and comply with all of the storage, handling, and preparation require-ments. If the patient is incapable, then a...